- Home
- IPSC vs CNTX Comparison
IPSC vs CNTX Comparison
Compare IPSC & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- CNTX
- Stock Information
- Founded
- IPSC 2019
- CNTX 2015
- Country
- IPSC United States
- CNTX United States
- Employees
- IPSC N/A
- CNTX N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- CNTX Health Care
- Exchange
- IPSC Nasdaq
- CNTX Nasdaq
- Market Cap
- IPSC 58.1M
- CNTX 60.7M
- IPO Year
- IPSC 2021
- CNTX 2021
- Fundamental
- Price
- IPSC $0.48
- CNTX $0.61
- Analyst Decision
- IPSC Strong Buy
- CNTX Strong Buy
- Analyst Count
- IPSC 5
- CNTX 5
- Target Price
- IPSC $4.67
- CNTX $6.50
- AVG Volume (30 Days)
- IPSC 480.0K
- CNTX 73.1K
- Earning Date
- IPSC 03-19-2025
- CNTX 03-20-2025
- Dividend Yield
- IPSC N/A
- CNTX N/A
- EPS Growth
- IPSC N/A
- CNTX N/A
- EPS
- IPSC N/A
- CNTX N/A
- Revenue
- IPSC $6,589,000.00
- CNTX N/A
- Revenue This Year
- IPSC N/A
- CNTX N/A
- Revenue Next Year
- IPSC N/A
- CNTX N/A
- P/E Ratio
- IPSC N/A
- CNTX N/A
- Revenue Growth
- IPSC 194.81
- CNTX N/A
- 52 Week Low
- IPSC $0.47
- CNTX $0.60
- 52 Week High
- IPSC $4.43
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- IPSC 26.49
- CNTX 36.08
- Support Level
- IPSC $0.54
- CNTX $0.64
- Resistance Level
- IPSC $0.59
- CNTX $0.99
- Average True Range (ATR)
- IPSC 0.05
- CNTX 0.09
- MACD
- IPSC -0.00
- CNTX -0.01
- Stochastic Oscillator
- IPSC 3.08
- CNTX 3.05
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.